These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2404444)

  • 1. Octreotide is effective in acromegaly but often results in cholelithiasis.
    Daughaday WH
    Ann Intern Med; 1990 Feb; 112(3):159-60. PubMed ID: 2404444
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide.
    Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF
    Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholelithiasis and acromegaly: therapeutic strategies.
    Montini M; Gianola D; Pagani MD; Pedroncelli A; Caldara R; Gherardi F; Bonelli M; Lancranjan I; Pagani G
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):401-6. PubMed ID: 8187305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of Sandostatin in acromegaly.
    Sassolas G
    Metabolism; 1992 Sep; 41(9 Suppl 2):39-43. PubMed ID: 1518432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of gallbladder contractility after withdrawal of long-term octreotide therapy in acromegalic patients.
    Shi YF; Zhu XF; Harris AG; Zhang JX; Deng JY
    Acta Endocrinol (Copenh); 1993 Sep; 129(3):207-12. PubMed ID: 8212985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term continuous infusion of octreotide in acromegaly. Pharmacokinetics and prediction of the response to long-term treatment.
    Timsit J; Chanson P; Harris AG; Grass P; Guillausseau PJ; Warnet A; Lubetzki J
    Horm Metab Res; 1991 Jan; 23(1):48-9. PubMed ID: 2016081
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatobiliary and gastrointestinal manifestations of acromegaly.
    Ezzat S
    Dig Dis; 1992; 10(3):173-80. PubMed ID: 1611713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
    Plöckinger U; Liehr RM; Quabbe HJ
    J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone and insulin-like growth factor-1 in blood and urine as response markers during treatment of acromegaly with octreotide: a double-blind placebo-controlled study.
    Fredstorp L; Werner S
    J Endocrinol Invest; 1993 Apr; 16(4):253-8. PubMed ID: 8514980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical management of acromegaly--what and when?
    Melmed S
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():13-7. PubMed ID: 8372605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
    Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly.
    Ezzat S; Ren SG; Braunstein GD; Melmed S
    J Clin Endocrinol Metab; 1991 Aug; 73(2):441-3. PubMed ID: 1713220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
    Ezzat S; Redelmeier DA; Gnehm M; Harris AG
    J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
    Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
    Vance ML; Harris AG
    Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly.
    Grunstein RR; Ho KK; Sullivan CE
    Ann Intern Med; 1994 Oct; 121(7):478-83. PubMed ID: 8067645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gall stones and treatment with octreotide for acromegaly.
    BMJ; 1989 Nov; 299(6708):1162-3. PubMed ID: 2513036
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment of gall bladder dynamics, cholecystokinin release and the development of gallstones during octreotide therapy for acromegaly.
    Ewins DL; Javaid A; Coskeran PB; Shah S; Butler J; Deprez PH; Miell J; Calam J; Barrett JJ; Dawson JM
    Q J Med; 1992 Apr; 83(300):295-306. PubMed ID: 1631261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octreotide treatment of acromegaly during pregnancy.
    Mikhail N
    Mayo Clin Proc; 2002 Mar; 77(3):297-8. PubMed ID: 11888040
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.